Association of inflammatory bowel disease incidence with isotretinoin usage: A meta-analysis and systematic review - 20/11/24
Doi : 10.1016/j.jaad.2024.11.003
Areeba Ahmed, MD a, Ayesha Liaquat, MBBS b, Saamia Raza, MBBS b, Eric Koza, BS a, Melissa Ma, BS a, Misha Haq, BS a, Victoria Shi, BA a, Ashhad Rabeegh, MD b, Michael D. Yi, BS a, Umer Nadir, BS a, Brian A. Cahn, MD c, Ross Pearlman, MD a, Daniel I. Schlessinger, MD a, Murad Alam, MD, MSCI, MBA a, d, e, ⁎ 
a Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
b Department of Dermatology, Dow University of Health Sciences, Karachi, Pakistan
c Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois
d Department of Otolaryngology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
e Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
∗Correspondence to: Murad Alam, MD, MSCI, MBA, Department of Dermatology, Feinberg School of Medicine, 676 N St Clair St, Suite 1600, Chicago, IL 60611Department of DermatologyFeinberg School of Medicine676 N St Clair StSuite 1600ChicagoIL60611
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 20 November 2024
Key words : acne, inflammatory bowel disease, isotretinoin
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?